Osteosarcoma: Trials and Tribulations in the Evolution of a Curative Strategy

Presentation Description: Osteosarcoma was initially considered to be a chemo-resistant tumor.  In the early 1970s high dose Methotrexate and amputation administered alone or in combination with other agents yielded a cure rate of 40-65 percent.  This result was challenged.  In this presentation, the saga of the controversy and the final acceptance of the regimen is described.


Norman Jaffe, MD, Dip Paed, DSc
Professor Emeritus
The University of Texas MD Anderson Cancer Centre, Houston, TX

Comments are closed.